111 related articles for article (PubMed ID: 37384847)
1. Association Between Oncology Clinical Pathway Utilization and Toxicity and Cost Outcomes in Patients With Metastatic Solid Tumors.
Liu Y; Mullangi S; Debono D; Chen X; Pham T; Fisch MJ; Gordon AS; Hershman DL
JCO Oncol Pract; 2023 Sep; 19(9):731-740. PubMed ID: 37384847
[TBL] [Abstract][Full Text] [Related]
2. Association of Patient, Physician, and Practice-Level Factors with Uptake of Payer-Led Oncology Clinical Pathways.
Mullangi S; Chen X; Pham T; Liu Y; Gordon AS; Debono D; Fisch MJ; Gönen M; Hershman DL
JAMA Netw Open; 2023 May; 6(5):e2312461. PubMed ID: 37159199
[TBL] [Abstract][Full Text] [Related]
3. Real-World Costs of Adverse Events in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer.
Engel-Nitz NM; Johnson MP; Bunner SH; Ryan KJ
J Manag Care Spec Pharm; 2020 Jun; 26(6):729-740. PubMed ID: 32463768
[TBL] [Abstract][Full Text] [Related]
4. Health Care Utilization and Costs Associated With Systemic First-Line Metastatic Melanoma Therapies in the United States.
van Boemmel-Wegmann S; Brown JD; Diaby V; Huo J; Silver N; Park H
JCO Oncol Pract; 2022 Jan; 18(1):e163-e174. PubMed ID: 34228489
[TBL] [Abstract][Full Text] [Related]
5. Factors Associated With Unmet Supportive Care Needs and Emergency Department Visits and Hospitalizations in Ambulatory Oncology.
Penedo FJ; Natori A; Fleszar-Pavlovic SE; Sookdeo VD; MacIntyre J; Medina H; Moreno PI; Crane TE; Moskowitz C; Calfa CL; Schlumbrecht M
JAMA Netw Open; 2023 Jun; 6(6):e2319352. PubMed ID: 37342038
[TBL] [Abstract][Full Text] [Related]
6. Healthcare utilization and cost of care in elderly breast cancer patients enrolled in SWOG clinical trials.
Hershman DL; Till C; Wright JD; Accordino M; Vaidya R; Barlow WE; Ramsey S; Unger JM
Breast Cancer Res Treat; 2020 Jun; 181(2):455-463. PubMed ID: 32306168
[TBL] [Abstract][Full Text] [Related]
7. Impact of cancer supportive care pathways compliance on emergency department visits and hospitalizations.
Kreys ED; Kim TY; Delgado A; Koeller JM
J Oncol Pract; 2014 May; 10(3):168-73. PubMed ID: 24839275
[TBL] [Abstract][Full Text] [Related]
8. Treatment patterns, clinical outcomes, health resource utilization, and cost in patients with BRCA-mutated metastatic breast cancer treated in community oncology settings.
Houts AC; Olufade T; Shenolikar R; Walker MS; Schwartzberg LS
Cancer Treat Res Commun; 2019; 19():100121. PubMed ID: 30785027
[TBL] [Abstract][Full Text] [Related]
9. Factors Associated with Adherence Rates for Oral and Intravenous Anticancer Therapy in Commercially Insured Patients with Metastatic Colon Cancer.
Seal BS; Anderson S; Shermock KM
J Manag Care Spec Pharm; 2016 Mar; 22(3):227-35. PubMed ID: 27003552
[TBL] [Abstract][Full Text] [Related]
10. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
11. Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.
Ramaswamy K; Lechpammer S; Mardekian J; Huang A; Schultz NM; Sandin R; Wang L; Baser O; George DJ
Adv Ther; 2020 May; 37(5):2083-2097. PubMed ID: 32112280
[TBL] [Abstract][Full Text] [Related]
12. Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study).
McArthur GA; Mohr P; Ascierto PA; Arance A; Banos Hernaez A; Kaskel P; Weichenthal M; Shinde R; Stevinson K
Oncologist; 2017 Aug; 22(8):951-962. PubMed ID: 28526721
[TBL] [Abstract][Full Text] [Related]
13. Impact of metastatic colorectal cancer stage and number of treatment courses on patient health care costs and utilization.
Chastek B; Kulakodlu M; Valluri S; Seal B
Postgrad Med; 2013 Mar; 125(2):73-82. PubMed ID: 23816773
[TBL] [Abstract][Full Text] [Related]
14. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
[TBL] [Abstract][Full Text] [Related]
15. The Impact of Adverse Events on Health Care Resource Utilization, Costs, and Mortality Among Patients Treated with Immune Checkpoint Inhibitors.
George S; Bell EJ; Zheng Y; Kim R; White J; Devgan G; Smith J; Lal LS; Engel-Nitz NM; Liu FX
Oncologist; 2021 Jul; 26(7):e1205-e1215. PubMed ID: 33955118
[TBL] [Abstract][Full Text] [Related]
16. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
[TBL] [Abstract][Full Text] [Related]
17. Association of Immune-Related Adverse Events, Hospitalization, and Therapy Resumption With Survival Among Patients With Metastatic Melanoma Receiving Single-Agent or Combination Immunotherapy.
Watson AS; Goutam S; Stukalin I; Ewanchuk BW; Sander M; Meyers DE; Pabani A; Cheung WY; Heng DYC; Cheng T; Monzon JG; Navani V
JAMA Netw Open; 2022 Dec; 5(12):e2245596. PubMed ID: 36480204
[TBL] [Abstract][Full Text] [Related]
18. Medical utilization associated with palivizumab compliance in a commercial and managed medicaid health plan.
Diehl JL; Daw JR; Coley KC; Rayburg R
J Manag Care Pharm; 2010; 16(1):23-31. PubMed ID: 20044844
[TBL] [Abstract][Full Text] [Related]
19. Health care utilization and steroid-refractory toxicities from immune checkpoint inhibitors.
Wang LX; Quach HT; Moodabigil NV; Davis EJ; Sosman JA; Dusetzina SB; Johnson DB
Cancer; 2020 Jan; 126(2):322-328. PubMed ID: 31580492
[TBL] [Abstract][Full Text] [Related]
20. Cost of Disease Progression in Patients with Metastatic Breast, Lung, and Colorectal Cancer.
Reyes C; Engel-Nitz NM; DaCosta Byfield S; Ravelo A; Ogale S; Bancroft T; Anderson A; Chen M; Matasar M
Oncologist; 2019 Sep; 24(9):1209-1218. PubMed ID: 30796156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]